Eyenovia, Inc. (EYEN)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Eyenovia, Inc. (EYEN)
Company Performance

Current Price

as of Oct 16, 2024

$0.55

P/E Ratio

N/A

Market Cap

$47.05M

Description

Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The firm is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression, and mydriasis. The company was founded by Sean Ianchulev on March 12, 2014 and is headquartered in New York, NY.

Metrics

Overview

  • HQNew York, NY
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerEYEN
  • Price$0.55+22.17%

Trading Information

  • Market Cap$47.05M
  • Float88.78%
  • Average Daily Volume (1m)863,747
  • Average Daily Volume (3m)1,662,347
  • EPS-$0.80

Company

  • Revenue$0.03M
  • Rev Growth (1yr)N/A
  • Net Income-$11.05M
  • Gross Margin-3,365.51%
  • EBITDA Margin-37,701.79%
  • EBITDA-$8.53M
  • EV$44.95M
  • EV/Revenue1,431.39
  • P/EN/A
  • P/S930.33
  • P/BN/A
Documents
SEC Filings
8-K (2024-09-30)
8-K (2024-09-20)
8-K (2024-09-03)
8-K (2024-08-23)
8-K (2024-08-22)
8-K (2024-08-13)
8-K (2024-07-29)
8-K (2024-07-05)
8-K (2024-07-01)
8-K (2024-06-14)
8-K (2024-06-04)
8-K (2024-05-16)
8-K (2024-05-15)
8-K (2024-04-10)
8-K (2024-04-09)
8-K (2024-04-08)
8-K (2024-03-19)
8-K (2024-01-25)
8-K (2024-01-16)
8-K (2023-11-13)
8-K (2023-09-20)
8-K (2023-08-29)
8-K (2023-08-16)
8-K (2023-08-10)
8-K (2023-06-27)
8-K (2023-05-23)
8-K (2023-05-11)
8-K (2023-05-08)
8-K (2023-03-30)
8-K (2023-02-28)
8-K (2023-02-15)
8-K (2023-01-30)
10-Q (2024-08-14)
10-Q (2024-05-15)
10-Q (2023-11-13)
10-Q (2023-08-11)
10-Q (2023-05-12)
10-K (2024-03-18)
10-K (2023-03-31)
Earnings Calls
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report 2023Q4
Earnings Report (2023-11-13)
Earnings Report (2023-08-13)
Factset Street Account
StreetAccount Earnings Call Q&A Summary: Eyenovia Q3 (2023-11-14T11:03:25Z)
Eyenovia reports Q3 EPS ($0.18) vs FactSet ($0.18) [4 est, ($0.21)-(0.15)] ($1.21, 0.00) (2023-11-13T21:11:58Z)
Eyenovia initiated outperform at William Blair ($1.30, 0.00) (2023-11-01T11:46:43Z)
Eyenovia announces FDA approval of Coastline International as contract manufacturer to initiate Mydcombi commercial production ($1.41, 0.00) (2023-11-02T11:24:59Z)
Factset
Factset Business Description